Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aviragen Therapeutics Resumes Enrollment in Phase 2a RSV Challenge Trial
ATLANTA , July 12, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, today announced it is resuming enrollment in its Phase 2a challenge study of BTA585, an oral
View HTML
Toggle Summary Aviragen Therapeutics and Georgia State University Research Foundation Enter Exclusive License and Sponsored Research Agreement to Develop Novel Antiviral Therapies
ATLANTA , July 05, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has entered into an exclusive, worldwide license and sponsored
View HTML
Toggle Summary Aviragen Therapeutics Announces Inducement Grant for New Employee
ATLANTA , July 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, announced today that the compensation committee of the Company's Board of Directors granted
View HTML
Toggle Summary Aviragen Therapeutics Announces the Appointment of Jonas Niaura as Vice President, Corporate Development and Strategy
ATLANTA , June 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced the appointment of Jonas Niaura as Vice President, Corporate Development and Strategy.
View HTML
Toggle Summary Aviragen Therapeutics Provides Update on Phase 2a Trial of BTA585 for the Treatment of RSV Infections
ATLANTA , May 26, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has voluntarily decided to delay further enrollment in the Phase 2a
View HTML
Toggle Summary Aviragen Therapeutics Reports Third Quarter Fiscal Year 2016 Financial Results
Conference Call to be Held Today at 4:30 P.M. ET
View HTML
Toggle Summary Aviragen Therapeutics to Host Conference Call to Report Third Quarter Fiscal Year 2016 Financial Results on May 5, 2016
ATLANTA , April 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc. ) a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, May 5, 2016 at 4:30
View HTML
Toggle Summary Aviragen Therapeutics Completes Royalty Deal With HealthCare Royalty Partners for Proceeds of $20 Million
Non-Dilutive Financing Provides for Company's Continued Participation in Future Royalties
View HTML
Toggle Summary Aviragen Therapeutics to Participate in FBR & Co. Healthcare Series Focused on Infectious Diseases
ATLANTA , April 14, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. , (NASDAQ:AVIR), formerly Biota Pharmaceuticals, Inc., today announced that Joseph Patti , PhD, President & CEO of Aviragen Therapeutics , will participate in a panel discussion titled, "Notable Emerging Anti-Viral Agents" as
View HTML
Toggle Summary Biota Pharmaceuticals, Inc. Announces Name Change to Aviragen Therapeutics, Inc. (NASDAQ: AVIR)
ATLANTA , April 12, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that the Company has changed its name to Aviragen Therapeutics, Inc. , ("Aviragen Therapeutics"), a pharmaceutical company focused on the development of the next generation of direct-acting
View HTML
Toggle Summary Biota Initiates Phase 2a Efficacy Study of BTA585 for the Treatment of RSV Infections
ATLANTA , April 11, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, today announced the initiation of its Phase 2a
View HTML
Toggle Summary Biota Pharmaceuticals to Present at 15th Annual Needham Healthcare Conference
ATLANTA , April 06, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO & President Joseph
View HTML
Toggle Summary Biota Pharmaceuticals Announces Sale of Antibiotic Assets to Spero Therapeutics
ATLANTA , March 17, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that it has completed the sale of assets related to its broad spectrum antibiotic program to a newly formed subsidiary of Spero Therapeutics, LLC , a Cambridge -based biopharmaceutical company
View HTML
Toggle Summary Biota Pharmaceuticals to Present at 28th Annual ROTH Conference
ATLANTA , March 07, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO &
View HTML
Toggle Summary Biota Announces Positive Results From Phase 1 Program for Direct Acting RSV Antiviral BTA585
Phase 2a RSV Challenge Study Planned for Q2 2016
View HTML

Log In

Create an account